Confirming risk before choosing
Late 60suntreated favorable-risk CLLboth durations still on the table
The full panel, or a single marker?
58%
Timing and individual markers
42%
The composite biology
What matters now
Frontline CLL therapy can now end on schedule. Three therapeutic paths are available at treatment initiation.
Late 60suntreated favorable-risk CLLboth durations still on the table
The full panel, or a single marker?
58%
Timing and individual markers
42%
The composite biology
Untreated CLLbiology permits optionsdistance and support limit delivery
The ramp you can staff, or the regimen's shape?
49%
Regimen shape and preference
51%
The early-window logistics
Frontline CLLmeaningful tumor burdencommunity practice, no easy inpatient backup
Tumor burden, or renal and metabolic markers?
53%
Renal function and uric acid
47%
Tumor burden measures
Newly diagnosed CLLdel(17p)/TP53 riskcardiac or bleeding comorbidity
One dominant risk, or the balance?
81%
The dominant risk
20%
The balance of risks
One year on a covalent BTK inhibitordisease controllednew AF or arthralgia
Stop the BTK inhibitor, or switch to keep control?
64%
The toxicity picture
36%
Continued disease control
What matters now
Frontline CLL therapy can now end on schedule. Three therapeutic paths are available at treatment initiation.
5 Real World Scenarios
Late 60suntreated favorable-risk CLLboth durations still on the table
The full panel, or a single marker?
Where does the evidence land?
58%
Timing and individual markers
42%
The composite biology
Untreated CLLbiology permits optionsdistance and support limit delivery
The ramp you can staff, or the regimen's shape?
Where does the evidence land?
49%
Regimen shape and preference
51%
The early-window logistics
Frontline CLLmeaningful tumor burdencommunity practice, no easy inpatient backup
Tumor burden, or renal and metabolic markers?
Where does the evidence land?
53%
Renal function and uric acid
47%
Tumor burden measures
Newly diagnosed CLLdel(17p)/TP53 riskcardiac or bleeding comorbidity
One dominant risk, or the balance?
Where does the evidence land?
81%
The dominant risk
20%
The balance of risks
One year on a covalent BTK inhibitordisease controllednew AF or arthralgia
Stop the BTK inhibitor, or switch to keep control?
Where does the evidence land?
64%
The toxicity picture
36%
Continued disease control